The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I don’t think you are quite right zwartkops. There is now no more then approx 5 months until results of ph3 trails. This is the big one, this will make or break the company. The second ph3 might be needed, but the share price and deals will be made on the 1st ph3 results, especially if they are amazing.
IMO it will now trade up to 50p+ over the next months in anticipation, it’s way to cheap for the risk v reward.
If you look at the monthly chart, looks like it turned end of last week, for its first up/buy trend in 2 years. While I am no chart expert and look at them loosely, I see it as a positive sign for the next few months of a steady uptrend.
All in my opinion, could be wrong...GL
results will be 50p. Price should steadily climb up to this over the next 6 months before results. Liberians note only supports what I have been saying for the past several months.
Looks at the potential, look at market cap, risk vs reward is huge right now. Price will rise to close that gap a little. A market cap of around 120m-150m prior to results will be right.
After results, all depends on the news I am afraid. Good, neutral or bad news will determine where price goes.
Good luck
Rhodi thought you were not buying until q4 when as you said the price will be 5p?????
You also said you would not be posting anymore.
It’s all in your posting history, black and white, from the past few weeks.
Haha your a funny person...I may not be able to spot a good investment, time will tell on that, but one thing I am good at is being able to spot dodgy shady characters, in person or on a board, as you all use the same language.
We had a conversation only few weeks back, where you stated several times you would not be buying until November when as you predict, the price will be 5p. You also stated you will not post anymore.
People say the funniest shite hey
At this valuation not really, this will rise to minimum 50p over the next several months, prior to phase 3 readout. I keep asking this question but no one answers it, how many companies have you come across that are only valued at approx 25m leading up to phase 3 readout for a potential blockbuster drug? It also has a decent chance of success as it is not a new drug.
Shares rise of potential, expectations and rumor, to a point where the risk vs rewards are balanced in some way. We are not there yet. That point I expect will be around 100m valuation, which is around 50p.
Let’s see, but I am happy to hold for this year. However it is guarantee that we will get large rises and falls along the way, which will have the associated Rampers and Bashers lurking around boards.
GLA
And hit 20p a few times through out the day, pushing through slightly at one point. Looks good for breaking 20p barrier tomorrow, if not next few days.
Lakshmi, I have been enjoying you technical updates mate, really interesting to see your live example graphs. Thanks.
GLA
Puk you have to agree there are a lot of ducks lined up nicely, but I am also in agreement that there is a very important duck missing, major deals/ launches.
Maybe, just maybe, they take a lot longer then we expect! This is what I hope the reason is anyway.
GLA
that this keeps on rising, showing that where it was @7p was drastically too far from where it should be. This hasn’t shotup by 100% and then retraced etc. It has just steadily rose by 5-10% daily for the past month.
There is a lot more to go over the remainder of the year, with both ups and downs. But leading up to phase 3 readout this should be atleast triple what it is today. Risk v reward. If ph3 is good, it will go to a couple £, if not good it will be back down here.
GLA
seems ticked with this company, apart from the announcement of big deals and so the high share price that would come with that.
I always ask myself this question, why would a $10bln company like DSMV not only invest and still hold a large quantity of shares in this company, but also have tied up with and invested several million into to setting up a global supply chain, If FF is dead in the water.
Say DSM didn’t realise it was going to be a flop, why continue to back it, continue to probably spend money on it, and continue to remain invested in it through DSMV.
Why would a $4bln company in China spend money on research and trials, and also try to get it approved for use in China, again for it to be a flop.
Basically I can’t think of any other answer, other than FF is considered useful and of monetary value.
Therefore I remain invested.
GLA
Hawk I recommended your post as I agree with you, but also you have misunderstood my post. I am saying that this will be somewhere between 50p-£1 prior to the phase 3 readout. As in it will rise to that space over the next 10months, with many ups and downs along the way.
That why I said rhodi isn’t making any sense, why would he be able to by in @ 5p at the end of the year, that market don’t work like that! 5p will be a distant memory and not hit again unless management seriously fk up along the way.
GLA
Anandas predictions are wacko, but not impossible of course, for it to happen all the planets need to align and that’s very unlikely.
But equally Rhodis predictions are wacko, buying in @ 5p in November just prior to a phase 3 read out. I don’t think I have ever seen that happen. But again not impossible, all the planets need to crash into each other and smash to pieces, basically the company would have to royally fk up over the next 10months.
50-100p prior to Phase 3 readout very likely IMO, but simply who knows.
GLA